Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Rhea-AI Summary

Abivax (Nasdaq: ABVX / Euronext: FR0012333284) filed its Universal Registration Document with the Autorité des Marchés Financiers and its Annual Report (Form 20-F) with the U.S. SEC. The 20-F filing date was March 23, 2026.

The Universal Registration Document contains the 2025 annual financial report, management and corporate governance reports, and statutory auditors' reports. Documents are available for download on Abivax, AMF, and SEC websites.

News Market Reaction – ABVX

+2.96%

3 alerts

+2.96% Session close to close

$9.48B Market Cap

0.3x Rel. Volume

In the Apr 2 session, ABVX gained 2.96%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement formalized Abivax’s 2025 reporting by filing its Universal Registration Document w...

Analysis

This announcement formalized Abivax’s 2025 reporting by filing its Universal Registration Document with the AMF and its Form 20-F with the U.S. SEC on March 23, 2026. The document bundles the 2025 annual financial report, corporate governance discussion, and statutory auditors’ reports, improving transparency for investors. In the context of recent clinical and corporate milestones, this step primarily consolidates disclosures. Investors may watch upcoming clinical readouts and subsequent filings to reassess the company’s risk-reward profile.

Key Figures

Filing date: March 23, 2026 Reporting year: 2025 Form 20-F: 20-F +1 more

4 metrics

Filing date March 23, 2026 Date of 20-F and Universal Registration Document filings

Reporting year 2025 Year covered by the annual financial report in the Universal Registration Document

Form 20-F 20-F Annual report form filed with the U.S. SEC

Announcement date April 1, 2026 Press release date for publication of financial reports

Historical Context

5 past events · Latest: Mar 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 23	Full-year results	Positive	-4.5%	Reported 2025 results, cash of €530.4M, and no new Phase 3 safety signals.
Feb 21	Clinical data update	Positive	+2.0%	Presented 22 ECCO abstracts with anti-fibrotic, efficacy, and safety data for obefazimod.
Jan 07	Corporate outlook	Positive	-8.7%	Outlined 2026 outlook, UC/CD plans, expected readouts, and runway into Q4 2027.
Dec 18	Index inclusion	Positive	+1.2%	Announced inclusion in the Nasdaq Biotechnology Index based on eligibility criteria.
Dec 17	Conference abstracts	Positive	+2.5%	Reported acceptance of 22 ECCO 2026 abstracts on obefazimod in inflammatory bowel disease.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often been positive, with mixed price reactions and several instances where favorable updates were followed by short-term declines.

Recent Company History

Over the last months, Abivax has reported multiple positive milestones. On Dec 17–18, 2025, it highlighted successful Phase 3 ABTECT induction data and entry into the Nasdaq Biotechnology Index, with modest gains. A Jan 7, 2026 outlook outlined obefazimod progress in UC and CD and a cash runway into Q4 2027, yet shares fell 8.69%. Subsequent ECCO 2026 data on Feb 21 and full-year 2025 results on Mar 23 brought further clinical and financial clarity but again produced mixed trading responses. Today’s regulatory filings follow that trajectory of frequent, information-rich updates.

Key Terms

universal registration document, 20-f, u.s. securities and exchange commission

3 terms

universal registration document regulatory

"announces the filing of its Universal Registration Document (Document d’Enregistrement Universel)"

A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.

20-f regulatory

"and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission"

A 20-F is an annual report that a non‑U.S. company files with U.S. regulators when its securities trade in the U.S.; it provides audited financial statements, business description, risk factors, and governance details. Investors use it like a comprehensive instruction manual—equivalent to a domestic company’s annual report—to assess a foreign issuer’s financial health, strategy, and risks before buying or holding its stock.

u.s. securities and exchange commission regulatory

"Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 23, 2026"

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

• Abivax publishes financial reports with the French and U.S. securities regulatory agencies
  

PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”),  a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 23, 2026.

The Universal Registration Document includes the 2025 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.

The documents will be available for download on the website of Abivax (www.abivax.com/investors), the AMF (www.amf-france.org), and the SEC (www.sec.gov/edgar).

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Attachment

• 2026_04_01_Abivax Publishes Financial Reports with Regulatory Agencies

FAQ

What documents did Abivax (ABVX) file with the AMF and SEC on March 23, 2026?

Abivax filed a Universal Registration Document with the AMF and a Form 20-F with the SEC. According to the company, the filings include the 2025 annual financial report, the management and corporate governance reports, and statutory auditors' reports.

When did Abivax (ABVX) submit its Annual Report (20-F) to the U.S. SEC?

Abivax submitted its Annual Report (Form 20-F) on March 23, 2026. According to the company, the 20-F accompanies the Universal Registration Document and covers the 2025 annual financial report and related governance disclosures.

Where can investors download Abivax (ABVX) regulatory filings including the 2025 annual report?

Investors can download filings from Abivax's investor website, the AMF site, and the SEC EDGAR database. According to the company, the Universal Registration Document and Form 20-F are available on those three sites for review and download.

What information is included in Abivax's Universal Registration Document for 2025?

The Universal Registration Document includes the 2025 annual financial report, management report, corporate governance report, and statutory auditors' reports. According to the company, these materials provide statutory and governance disclosures for the 2025 fiscal year.

Does Abivax's (ABVX) filing of the 20-F and Universal Registration Document change its clinical or financial status?

The filings document prior-year financials and governance disclosures but do not by themselves change clinical or financial status. According to the company, the documents present the 2025 reports and auditor statements for investor review.